Noxopharm aims for autoimmune market with first human trial of SOF-SKN
Noxopharm Ltd is planning the first human trial to assess novel drug SOF-SKN, which aims to treat autoimmune conditions.
NPX
0.00%
$5.25
NUPLEX INDUSTRIES LIMITED. - Corporate Spotlight
Currently unlisted.
Add to my watchlist
Corporate Spotlight
Not Yet Available
Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.
No Corporate Spotlight currently available.